Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02079883 · ClinicalTrials.gov registry record
Ocriplasmin Research to Better Inform Treatment (ORBIT)
A clinical trial, sponsored by ThromboGenics.
- Completed
- Registry status
- 540
- Enrollment target
NCT02079883: Completed study, sponsored by ThromboGenics.
NCT02079883 is a clinical trial that has completed, run by ThromboGenics. The registered enrollment target is 540 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02079883 has completed, sponsored by ThromboGenics.
- COMPLETED
- Registry status
- 540 participants
- Enrollment target
Study Summary
This is a multicenter, prospective, observational, Phase 4 study that will assess clinical outcomes and safety of JETREA® administered in a real-world setting for the treatment of symptomatic vitreomacular adhesion (VMA) by assessing anatomical and functional outcomes in 1500 patients recruited across approximately 120 USA retina sites.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 540 participants |
| Start Date | 2014-05 |
| Est. Completion | 2016-05 |
What the finished NCT02079883 record still lists
NCT02079883 is an observational study that tracks outcomes without assigning an intervention. The registered 540 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT02079883 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02079883 about?
NCT02079883 is a clinical study titled "Ocriplasmin Research to Better Inform Treatment (ORBIT)". This is a multicenter, prospective, observational, Phase 4 study that will assess clinical outcomes and safety of JETREA® administered in a real-world setting for the treatment of symptomatic vitreomacular adhesion (VMA) by assessing anatomical and functional outcomes in 1500 patients recruited acro...
What is the current status of trial NCT02079883?
This trial is currently completed. The enrollment target is 540 participants. The study started on 2014-05. Estimated completion is 2016-05.
Who is sponsoring clinical trial NCT02079883?
This trial is sponsored by ThromboGenics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04557462 · 540 participants · Phase 3
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
- NCT04956640 · 540 participants · Phase 1
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
- NCT05429892 · 540 participants · NA
FRESH Delivers: An Innovative Approach to Reducing Tobacco Use Among Rural Smokers
- NCT05549297 · 540 participants · Phase 3
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia